Market capitalization | $10.39b |
Enterprise Value | $9.39b |
P/E (TTM) P/E ratio | 23.18 |
EV/FCF (TTM) EV/FCF | 21.71 |
EV/Sales (TTM) EV/Sales | 4.51 |
P/S ratio (TTM) P/S ratio | 4.99 |
P/B ratio (TTM) P/B ratio | 4.57 |
Revenue growth (TTM) Revenue growth | 17.31% |
Revenue (TTM) Revenue | $2.08b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
23 Analysts have issued a Exelixis, Inc. forecast:
23 Analysts have issued a Exelixis, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,082 2,082 |
17%
17%
|
|
Gross Profit | 2,004 2,004 |
17%
17%
|
|
EBITDA | 636 636 |
635%
635%
|
EBIT (Operating Income) EBIT | 608 608 |
1,383%
1,383%
|
Net Profit | 467 467 |
407%
407%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Head office | United States |
CEO | Michael Morrissey |
Employees | 1,310 |
Founded | 1994 |
Website | www.exelixis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.